Xeris Biopharma (XERS) Competitors $7.74 +0.07 (+0.85%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XERS vs. CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, and MIRMShould you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Xeris Biopharma vs. Its Competitors CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals Xeris Biopharma (NASDAQ:XERS) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Do institutionals & insiders have more ownership in XERS or CRSP? 42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, XERS or CRSP? Xeris Biopharma has higher revenue and earnings than CRISPR Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$203.07M6.17-$54.84M-$0.21-36.95CRISPR Therapeutics$37.31M148.76-$366.25M-$5.43-11.24 Which has more volatility and risk, XERS or CRSP? Xeris Biopharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Is XERS or CRSP more profitable? Xeris Biopharma has a net margin of -13.01% compared to CRISPR Therapeutics' net margin of -1,229.43%. Xeris Biopharma's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xeris Biopharma-13.01% N/A -8.00% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Does the media prefer XERS or CRSP? In the previous week, CRISPR Therapeutics had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 8 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.96 beat CRISPR Therapeutics' score of 0.92 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer XERS or CRSP? Xeris Biopharma currently has a consensus target price of $7.08, indicating a potential downside of 8.72%. CRISPR Therapeutics has a consensus target price of $71.50, indicating a potential upside of 17.17%. Given CRISPR Therapeutics' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryXeris Biopharma beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks. Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XERS vs. The Competition Export to ExcelMetricXeris BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25B$2.53B$5.74B$10.30BDividend YieldN/A59.99%5.86%4.62%P/E Ratio-36.9523.2976.8026.52Price / Sales6.17486.45448.8087.93Price / CashN/A169.8537.2260.63Price / Book-38.805.2914.066.31Net Income-$54.84M$32.95M$3.29B$271.37M7 Day Performance1.04%-1.29%-0.77%0.57%1 Month Performance5.43%3.50%3.84%6.20%1 Year Performance167.59%-3.48%87.65%28.33% Xeris Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XERSXeris Biopharma2.8097 of 5 stars$7.74+0.8%$7.08-8.4%+164.5%$1.25B$203.07M-36.97290Gap UpCRSPCRISPR Therapeutics3.3714 of 5 stars$54.10-1.4%$71.60+32.3%+18.4%$4.99B$37.31M-9.96460Analyst ForecastPTCTPTC Therapeutics3.6999 of 5 stars$56.95-0.5%$69.00+21.2%+72.9%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.9327 of 5 stars$145.20-3.4%$210.38+44.9%-18.6%$4.35B$290.52M29.51210Positive NewsAnalyst ForecastPCVXVaxcyte2.1957 of 5 stars$32.41-1.8%$130.00+301.1%-73.5%$4.29BN/A-7.89160Positive NewsACADACADIA Pharmaceuticals4.3718 of 5 stars$25.39+0.5%$28.88+13.7%+48.8%$4.26B$957.80M19.09510ACLXArcellx2.1206 of 5 stars$71.11-2.1%$114.31+60.7%-2.0%$4.03B$107.94M-20.7980ADMAADMA Biologics3.5177 of 5 stars$16.42-2.7%$27.67+68.5%-16.8%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1372 of 5 stars$27.17-6.6%$43.14+58.8%+45.6%$4.02B$3.55M-21.23400Trending NewsInsider TradeAnalyst RevisionMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageGap UpHigh Trading VolumeMIRMMirum Pharmaceuticals3.2394 of 5 stars$77.39+1.7%$74.13-4.2%+81.5%$3.82B$336.89M-63.96140Positive News Related Companies and Tools Related Companies CRSP Alternatives PTCT Alternatives KRYS Alternatives PCVX Alternatives ACAD Alternatives ACLX Alternatives ADMA Alternatives ARWR Alternatives MENS Alternatives MIRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XERS) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
